For most people who qualify, Wegovy delivers significant weight loss that’s difficult to achieve through diet and exercise alone. Clinical trials show an average loss of about 15% of body weight over 68 weeks, with cardiovascular benefits on top of that. But the answer depends on your budget, your tolerance for side effects, and whether you’re prepared to stay on the medication long term, because the weight comes back when you stop.
How Much Weight You Can Expect to Lose
In the landmark STEP 1 trial, people without type 2 diabetes lost an average of 14.9% of their body weight over 68 weeks on Wegovy, compared to just 2.4% on placebo. For someone starting at 250 pounds, that translates to roughly 37 pounds. When paired with intensive behavioral therapy and a low-calorie diet in the STEP 3 trial, results were even better: 16% average weight loss.
People with type 2 diabetes tend to lose less. The STEP 2 trial showed an average reduction of 9.6%, which is still meaningful but noticeably lower. This is a consistent pattern with all GLP-1 medications.
Longer-term data is encouraging. In the STEP 5 trial, participants maintained a 15.2% weight reduction at two full years of treatment. The weight loss isn’t a quick spike that fades while you’re still taking the drug. It holds as long as you keep going.
How Wegovy Compares to Zepbound
The most relevant comparison is Zepbound (tirzepatide), which works on two gut hormones instead of one. In a head-to-head trial over 72 weeks, Zepbound produced 20.2% average weight loss compared to Wegovy’s 13.7%. That’s roughly 50 pounds lost versus 33 pounds for a typical participant. Nearly 65% of people on Zepbound hit the 15% weight loss mark, compared to 40% on Wegovy.
Zepbound also led to greater reductions in waist circumference: 7.2 inches versus 5.1 inches. If pure weight loss is your primary measure of “worth it,” Zepbound has a clear edge. However, availability, insurance coverage, and individual response all vary, so Wegovy remains a strong option, especially for people whose insurers cover it but not the alternative.
The Side Effects Are Common but Usually Manageable
Gastrointestinal problems are the main downside. In pooled clinical trial data, 44% of people on Wegovy experienced nausea, 30% had diarrhea, 25% dealt with vomiting, and 24% reported constipation. These rates are significantly higher than placebo.
For most people, these side effects are worst during the dose escalation phase (the first 16 to 20 weeks, as the dose gradually increases) and tend to improve over time. They’re the number one reason people discontinue treatment in clinical trials. If you’re someone who’s highly sensitive to nausea, this is worth factoring into your decision.
More serious concerns like pancreatitis and gastroparesis (stomach paralysis) have been reported in case studies, but the precise rates remain unknown. These are rare enough that large trials haven’t pinned down exact numbers, but they’re not zero risk.
Weight Comes Back When You Stop
This is the single biggest factor in deciding whether Wegovy is “worth it,” because it reframes the question. You’re not paying for a course of treatment with a defined end point. You’re committing to an ongoing medication.
A 2025 systematic review published in The BMJ found that people regain an estimated 9.9 kg (about 22 pounds) within the first year of stopping newer medications like Wegovy and Zepbound, at a rate of roughly 0.8 kg (1.8 pounds) per month. The projected return to baseline weight is about 1.5 years after stopping. In other words, within a year and a half of quitting, the average person is back where they started.
This doesn’t mean the medication “doesn’t work.” It means obesity functions more like a chronic condition requiring ongoing management, similar to blood pressure medication. If you stop treating it, the underlying biology reasserts itself. For many people, that makes the cost calculation not “how much for 68 weeks” but “how much per year, indefinitely.”
What It Actually Costs
Novo Nordisk has introduced a subscription pricing model for people paying out of pocket. Injectable Wegovy ranges from $249 per month on a 12-month plan to $329 per month on a 3-month plan. New patients on lower starting doses pay $199 per month for the first two months. The higher-dose pen starts at $399 per month for self-pay patients.
If you have commercial insurance that covers Wegovy, the manufacturer’s savings card can bring your copay down to as little as $25 per month, with a maximum savings of $100 per month. The catch is getting your insurer to approve it in the first place.
Getting Insurance to Cover It
Coverage varies widely and often comes with hurdles. Most commercial plans that cover Wegovy require a BMI over 30, or a BMI over 27 with at least one weight-related condition like high blood pressure or sleep apnea. Some plans set the bar even higher than the FDA label suggests.
Beyond BMI, expect additional requirements. Eight out of eleven major plans studied required a reduced-calorie diet and increased physical activity. Seven required enrollment in a behavioral modification program, with six of those requiring it before you even start the medication. One plan required patients to try older, less expensive weight loss drugs first.
Approval periods are often short, ranging from 12 weeks to 2 years, and every plan with continuation criteria required documented weight loss of at least 4% to 5% to keep the prescription going. Some also required your BMI to drop to 25 or below. If you don’t hit those targets, coverage can be pulled.
Benefits Beyond the Scale
Weight loss alone doesn’t capture the full picture. The SELECT trial, which followed over 17,000 participants with pre-existing heart disease, found that Wegovy reduced major cardiovascular events (heart attacks, strokes, and cardiovascular death) by 20% compared to placebo. For people with heart failure specifically, the benefit was even more pronounced, with a 28% to 35% reduction in risk depending on the type of heart failure.
These cardiovascular benefits are a major reason Wegovy earned a separate FDA indication for reducing heart risk in people with obesity and established cardiovascular disease. If you have heart disease or significant cardiovascular risk factors, the value proposition shifts considerably. You’re not just paying for weight loss; you’re paying for measurable protection against heart attacks and strokes.
What “Worth It” Really Depends On
Wegovy is worth it for people who can afford the ongoing cost (whether through insurance or out of pocket), who have enough weight to lose that a 14% to 15% reduction meaningfully improves their health, and who understand this is likely a long-term commitment. The cardiovascular benefits add real value for anyone with heart disease risk.
It may be less worth it if you’re paying entirely out of pocket without a clear plan for sustaining that expense, if you’re comparing it against Zepbound and have access to both, or if you’re expecting to use it for a defined period and then stop. The weight regain data makes that last scenario particularly discouraging. The medication works well while you take it. The question is whether you can keep taking it.